A phase I open-label multicentre dose-escalation study of subcutaneous ALM201 in patients with advanced ovarian cancer and other solid tumours.
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2016
At a glance
- Drugs ALM 201 (Primary)
- Indications Ovarian cancer; Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Almac Discovery
- 11 Oct 2016 Trial design presented at 41st European Society for Medical Oncology Congress.
- 04 Apr 2015 Status changed from planning to recruiting as per European Clinical Trials Database.
- 06 May 2013 New trial record